https://www.taxtmi.com/caselaws?id=796782 Bulk drugs and active pharmaceutical ingredients (APIs) imported for formulation manufacture, testing, analysis, clinical research, clinical trials, bioavailability studies or bioequivalence studies qualify as drugs under Serial No. 226 of Schedule I to the IGST rate notification. The inclusive definition of "drug" covers substances intended for use as drug components, and the bulk-drug definition confirms that APIs are pharmaceutical substances used directly or as formulation ingredients. Import licences also treat APIs as drugs. Their intended research or testing use does not alter that character. The specific description-based entry for drugs applies regardless of chapter classification and prevails over general chemical entries. Imports attract 5% IGST unless covered by the nil-rated Serial No. 113 entry. en-us Fri, 07 Aug 2026 00:00:00 +0530 Tue, 11 Aug 2026 08:46:56 +0530 TaxTMI RSS Generator https://www.taxtmi.com/caselaws?id=796782 Bulk drugs and active pharmaceutical ingredients (APIs) imported for formulation manufacture, testing, analysis, clinical research, clinical trials, bioavailability studies or bioequivalence studies qualify as drugs under Serial No. 226 of Schedule I to the IGST rate notification. The inclusive definition of "drug" covers substances intended for use as drug components, and the bulk-drug definition confirms that APIs are pharmaceutical substances used directly or as formulation ingredients. Import licences also treat APIs as drugs. Their intended research or testing use does not alter that character. The specific description-based entry for drugs applies regardless of chapter classification and prevails over general chemical entries. Imports attract 5% IGST unless covered by the nil-rated Serial No. 113 entry. Case-Laws Customs Fri, 07 Aug 2026 00:00:00 +0530 https://www.taxtmi.com/caselaws?id=796782